Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for mGluR2 (GRM2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | mGluR2 Lentivirus Premade Particles Optimized for stable cell line generation. Sequence Verified. |
View mGluR2 Products |
| Gene Delivery | mGluR2 Promise-ORF Full-length ORF for stable cell lines. |
View mGluR2 Products |
| Benchmark Ab | Anti-mGluR2 Reference Antibody Recombinant positive control for assay validation. |
View mGluR2 Products |
| Validator | mGluR2 siRNA Set For knockdown verification. |
View mGluR2 Products |
| Related Target A | mGluR3 (GRM3) Critical for mGluR2/3 selectivity and counter-screening. |
View mGluR3 Products |
| Related Target B | mGluR5 (GRM5) Synergistic target in glutamate signaling network. |
View mGluR5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | Lentivirus Premade Particles for native expression in host cells (e.g., HEK293) |
| High Homology Counter Screening | mGluR3 (GRM3) reagents available for rigorous selectivity assays |
| Lack of Controls | Clinical Benchmark Antibodies included for validation |
| False Positives | Validated siRNA included for specificity checks |
Live mGluR2 (GRM2) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for mGluR2 therapeutics is intensifying, with major players shifting focus from traditional orthosteric agonists to Positive Allosteric Modulators (PAMs). As first-generation therapies reach the clinic, the next wave of R&D is targeting unprecedented selectivity over mGluR3 to mitigate off-target effects in schizophrenia and depression treatments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAM) | Janssen, Eli Lilly | Schizophrenia, Depression | Cell-based Functional Assay (Need Lentivirus for Cell Line) |
| Small Molecule (NAM) | Novartis, Addex | Cognitive Impairment | Selectivity Screening (Need mGluR3 counter-targets) |
| Nanobody / mAb | Preclinical biotech | Neuroinflammation | Conformational Epitope Validation (Need stable expression) |